The De-Extincting Science in Jurassic World Is Right Around the Corner
By Maddie Stone,
Gizmodo
| 06. 10. 2015
Untitled Document
Twenty five years ago, Michael Crichton captured our imaginations with the crazy idea that scientists might one day resurrect dinosaurs. But on the eve of Jurassic World’s release a quarter century later, the prospect of bringing back extinct creatures is looking a lot less science fictional.
We’ll probably never bring back Tyrannosaurus rex. (Mosquitos with perfectly preserved dino DNA in their guts are a bit like magical leprechauns, though scientists did recently discover what they believe is dinosaur blood in fossils). But for species we’ve driven extinct in recent history, from the passenger pigeon to the Chinese river dolphin to the gastric brooding frog and even the woolly mammoth, we may yet be able to reverse time, thanks to incredible advances in genomics and synthetic biology.
In tribute to our undying love for massive reptilian killing machines, and the impossible dream that they’ll one day rule the Earth again, let’s explore the science of de-extincting life.
Awakening the Dead
On a midsummer’s day in 2003, a group of Spanish and French scientists helped a goat...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...